How does atogepant alleviate migraine pain?

Atogepant exerts its therapeutic effects by blocking CGRP receptors. CGRP, or calcitonin gene-related peptide, is a neuropeptide that plays a crucial role in migraine pathophysiology. During a migraine attack, CGRP is released, leading to vasodilation, neurogenic inflammation, and transmission of pain signals. By blocking CGRP receptors, atogepant effectively interrupts this cascade of events, helping to reduce the intensity and frequency of migraine attacks. This mechanism of action targets the underlying cause of migraines, making atogepant a promising option for individuals seeking relief from migraine pain.